Bardoxolone methyl capsules ( DrugBank: Bardoxolone methyl, Bardoxolone )

---

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
66	IgA腎症	1
67	多発性嚢胞腎	1
86	肺動脈性肺高血圧症	1
222	一次性ネフローゼ症候群	1

66. IgA腎症

---

臨床試験数 : 275 /  薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03366337 (ClinicalTrials.gov)	December 26, 2017	4/12/2017	A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX	A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases	IgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic Kidney	Drug: Bardoxolone methyl capsules	Reata Pharmaceuticals, Inc.	NULL	Completed	18 Years	65 Years	All	103	Phase 2	United States

67. 多発性嚢胞腎

---

臨床試験数 : 221 /  薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03366337 (ClinicalTrials.gov)	December 26, 2017	4/12/2017	A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX	A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases	IgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic Kidney	Drug: Bardoxolone methyl capsules	Reata Pharmaceuticals, Inc.	NULL	Completed	18 Years	65 Years	All	103	Phase 2	United States

86. 肺動脈性肺高血圧症

---

臨床試験数 : 1,205 /  薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02657356 (ClinicalTrials.gov)	October 4, 2016	13/1/2016	Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST	A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension	Connective Tissue Disease-Associated Pulmonary Arterial Hypertension	Drug: Placebo capsules;Drug: Bardoxolone methyl capsules	Reata Pharmaceuticals, Inc.	NULL	Terminated	18 Years	75 Years	All	202	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;Germany;Israel;Japan;Mexico;Netherlands;Philippines;Spain;United Kingdom;Chile;Czech Republic

222. 一次性ネフローゼ症候群

---

臨床試験数 : 310 /  薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03366337 (ClinicalTrials.gov)	December 26, 2017	4/12/2017	A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX	A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases	IgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic Kidney	Drug: Bardoxolone methyl capsules	Reata Pharmaceuticals, Inc.	NULL	Completed	18 Years	65 Years	All	103	Phase 2	United States